2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.
Ana Christina Garrido-Castro, MD, medical oncologist, co-director, Triple-Negative Breast Cancer Working Group, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses findings from the phase 2 SACI-IO HR+ trial (NCT04448886) evaluating sacituzumab govitecan-hziy (Trodelvy) with or without pembrolizumab (Keytruda) in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.
Related Content: